Teva and Samsung Bioepis Sign US Commercialisation Deal for Two FDA-Approved Biosimilars
What the Teva deal means for the US biosimilars market: two older TNF biosimilars, a staggered rights transfer and financial terms still undisclosed.
Tag: TNF inhibitor biosimilars
Read More